Growth Hormone Stimulation Test By Insulin at Chughtai Lab

Growth Hormone Stimulation Test By Insulin at Chughtai Lab

The Growth Hormone Stimulation Test by Insulin, clinically referred to as the Insulin Tolerance Test (ITT), is widely recognized as the gold standard diagnostic investigation for evaluating growth hormone (GH) reserve and the integrity of the hypothalamic-pituitary-adrenal (HPA) axis. Administered under strict medical supervision at Chughtai Lab, this specialized dynamic endocrine test plays a pivotal role in diagnosing growth hormone deficiency (GHD) in both pediatric and adult populations. Unlike static hormone measurements, which can be highly variable due to the pulsatile nature of growth hormone secretion, a stimulation test provides a definitive assessment of the pituitary gland’s functional capacity under physiological stress.

Growth hormone is synthesized and secreted by somatotroph cells in the anterior pituitary gland. Its release is regulated by a complex feedback loop involving hypothalamic Growth Hormone-Releasing Hormone (GHRH), which stimulates secretion, and Somatostatin, which inhibits it. Because GH is secreted in sporadic, short-lived pulses throughout the day—often peaking during deep sleep—a single random blood sample is clinically insufficient to diagnose deficiency. A patient with normal growth hormone levels may show an undetectable level on a random draw. To overcome this diagnostic challenge, endocrinologists utilize provocative stimulation tests. The insulin-induced hypoglycemia test is the most robust of these, as it directly triggers a central counter-regulatory stress response, forcing the pituitary gland to release its stored reserves of growth hormone and adrenocorticotropic hormone (ACTH).

During the procedure, a calculated dose of regular insulin is administered intravenously to safely lower the patient’s blood glucose level to less than 40 mg/dL (or a reduction of more than 50% from the baseline value). This state of controlled hypoglycemia acts as a powerful physiological stressor. In individuals with normal pituitary function, the hypothalamus detects this energy crisis and signals the anterior pituitary to release counter-regulatory hormones, primarily growth hormone and cortisol, to help restore glucose homeostasis. By measuring the rise of these hormones in subsequent blood samples, clinical pathologists and endocrinologists can accurately determine whether the pituitary gland possesses adequate functional reserve or if there is an underlying pituitary insufficiency.

Clinical Procedure: What to Expect

Patient Preparation

Due to the dynamic nature of this test and the physiological stress induced by hypoglycemia, strict adherence to patient preparation guidelines is mandatory to ensure both safety and diagnostic accuracy. Patients must follow these instructions carefully before arriving at Chughtai Lab:

• Overnight Fasting: The patient must remain completely fasting (nil by mouth) for at least 8 to 12 hours prior to the test. Only plain water is permitted. This is crucial because food intake suppresses growth hormone secretion and prevents the achievement of target hypoglycemia.
• Medication Review: Patients must inform their prescribing physician and the laboratory staff of all current medications. Certain drugs, particularly glucocorticoids, thyroid hormones, and estrogen therapies, can significantly affect growth hormone secretion and must be managed or temporarily paused under medical supervision.
• Euthyroid State: It is highly recommended that the patient is euthyroid (has normal thyroid hormone levels) before undergoing GH stimulation testing, as hypothyroidism can cause false-subnormal growth hormone responses.
• Rest and Activity: Strenuous physical exercise must be avoided for 24 hours prior to the test, as physical exertion naturally stimulates growth hormone release and can skew baseline measurements.
• Accompanying Adult: Because the test involves inducing hypoglycemia, which can cause temporary dizziness, sweating, or mild confusion, patients must be accompanied by a responsible adult who can assist them after the procedure.
• Prior Screening: The test is contraindicated in patients with a history of epilepsy, severe cardiovascular disease, ischemic heart disease, or untreated adrenal insufficiency. A thorough clinical clearance by an endocrinologist is required before scheduling.

During the Procedure

The Growth Hormone Stimulation Test by Insulin is conducted in a highly controlled clinical environment at Chughtai Lab, under the direct supervision of qualified medical professionals prepared to manage hypoglycemia. The step-by-step process includes:

• Intravenous Access: An indwelling intravenous (IV) cannula is inserted into a vein in the patient’s arm. This cannula remains in place throughout the test, allowing for painless, repeated blood sampling and immediate access for therapeutic intervention if required.
• Baseline Sampling (Time 0): Initial blood samples are drawn to measure baseline levels of growth hormone, cortisol, and blood glucose.
• Insulin Administration: A precise dose of regular (rapid-acting) insulin, typically calculated at 0.1 to 0.15 units per kilogram of body weight, is administered intravenously through the cannula. The exact dose is customized by the supervising clinician based on the patient’s clinical history and suspected insulin sensitivity.
• Serial Blood Collection: Blood samples are drawn at pre-specified intervals—typically at 15, 30, 45, 60, 90, and 120 minutes post-insulin injection. Each sample is analyzed for both glucose and growth hormone levels (and often cortisol).
• Hypoglycemia Verification: For the test to be considered diagnostically valid, the blood glucose level must drop below 40 mg/dL (2.2 mmol/L) and the patient must exhibit clinical signs of mild hypoglycemia (such as sweating, mild palpitations, or warmth).
• Continuous Monitoring: A dedicated nurse or physician continuously monitors the patient’s vital signs, level of consciousness, and clinical symptoms.
• Safety and Rescue Protocol: If severe neuroglycopenia occurs (e.g., extreme confusion, seizure activity, or loss of consciousness), the test is immediately terminated, and concentrated intravenous dextrose (25% or 50%) along with intravenous hydrocortisone is administered through the cannula to rapidly restore normal blood glucose levels.
• Post-Test Recovery: Once the final blood sample is collected at the 120-minute mark, the patient is given a high-carbohydrate meal or sweet drink to restore normal blood glucose levels. The patient is monitored until they are fully asymptomatic and safe to be discharged.

When is a Growth Hormone Stimulation Test By Insulin Performed?

Evaluation of Pediatric Short Stature and Growth Failure

In pediatric medicine, this test is primarily indicated when a child exhibits significant growth failure, characterized by a growth velocity below the 25th percentile for age, or a height that falls more than two standard deviations below the mean for their age and sex. Pediatric endocrinologists utilize the insulin stimulation test to differentiate between familial short stature, constitutional delay of growth, and true organic growth hormone deficiency. Confirming a diagnosis of GHD is essential, as it qualifies the child for recombinant human growth hormone (rhGH) therapy, which can normalize adult height outcomes.

Diagnosis of Adult Growth Hormone Deficiency (AGHD)

Adult Growth Hormone Deficiency is a distinct clinical syndrome characterized by altered body composition (increased visceral adiposity, decreased muscle mass), reduced bone mineral density, abnormal lipid profiles, impaired cardiovascular function, and a significantly diminished quality of life. Because GH levels naturally decline with age, static measurements are useless in adults. The insulin tolerance test is the preferred diagnostic tool to confirm severe AGHD in patients with suspected hypothalamic-pituitary disease, allowing them to benefit from growth hormone replacement therapy.

Assessment of Hypopituitarism and Pituitary Tumors

Pituitary adenomas, craniopharyngiomas, and other sellar or suprasellar tumors can physically compress the anterior pituitary gland or the pituitary stalk, disrupting normal hormone production. The insulin stimulation test is performed to assess the functional reserve of the somatotrophs and the corticotrophs in these patients. It helps determine if the tumor or its mass effect has caused partial or complete hypopituitarism, which is vital for planning comprehensive hormone replacement strategies.

Post-Radiotherapy or Post-Surgical Pituitary Evaluation

Patients who have undergone neurosurgery (such as transsphenoidal resection of a pituitary tumor) or cranial radiation therapy for brain tumors are at a high risk of developing progressive pituitary hormone deficiencies over time. Somatotrophs are often the most sensitive cells to radiation damage. Endocrinologists schedule this test at specific post-treatment intervals to monitor for the onset of growth hormone deficiency and to evaluate the integrity of the hypothalamic-pituitary-adrenal axis.

Investigation of Multiple Pituitary Hormone Deficiencies (MPHD)

When a patient is known to have at least one pituitary hormone deficiency (such as central hypothyroidism or hypogonadotropic hypogonadism), the probability of having co-existing growth hormone deficiency is highly elevated. The insulin tolerance test serves as a comprehensive dynamic evaluation, simultaneously assessing both the growth hormone axis and the adrenal axis (via ACTH-stimulated cortisol release), providing a detailed map of pituitary function in patients with suspected multi-axis failure.

What Does a Growth Hormone Stimulation Test By Insulin Detect?

The Growth Hormone Stimulation Test by Insulin is highly sensitive and detects a wide range of physiological and pathological endocrine states, including:

• Severe Growth Hormone Deficiency (Adults): Confirmed when the peak growth hormone response to verified hypoglycemia is less than 3.0 ng/mL.
• Severe Growth Hormone Deficiency (Children): Indicated when the peak growth hormone level fails to rise above 7.0 ng/mL (or 10.0 ng/mL depending on specific clinical guidelines) during the test.
• Partial Growth Hormone Deficiency: Characterized by a subnormal peak response that is higher than the severe deficiency threshold but lower than the normal physiological response.
• Normal Somatotroph Function: Indicated by a robust peak growth hormone level exceeding 10.0 ng/mL in children or 5.0 ng/mL in adults, ruling out growth hormone deficiency.
• Adrenal Insufficiency (Secondary): Detected if the cortisol level fails to rise above 18 mcg/dL (500 nmol/L) at the peak of insulin-induced hypoglycemia, indicating a failure of the hypothalamic-pituitary-adrenal axis.
• Panhypopituitarism: Indicated by a flatline response in both growth hormone and cortisol levels, confirming generalized anterior pituitary failure.
• Isolated Growth Hormone Deficiency: Confirmed when the growth hormone response is deficient but the cortisol response (HPA axis) remains completely normal.
• Pituitary Stalk Interruption Syndrome: Characterized by severe, multi-hormonal deficiencies detected via subnormal responses of GH and other pituitary-dependent hormones.
• Sheehan’s Syndrome: Postpartum pituitary necrosis resulting in a failure of the pituitary gland to respond to hypoglycemia with an increase in GH or cortisol.
• Empty Sella Syndrome: Endocrine dysfunction associated with anatomical herniation of the subarachnoid space into the sella turcica, leading to impaired GH reserve.
• Radiation-Induced Pituitary Damage: Gradual loss of somatotroph secretory capacity detected years after cranial radiation therapy.
• Traumatic Brain Injury (TBI) Induced Hypopituitarism: Pituitary dysfunction resulting from shear injury to the pituitary stalk or direct trauma to the gland.
• Craniopharyngioma-Related Pituitary Insufficiency: Destruction of pituitary tissue by a benign tumor, leading to a flat GH stimulation curve.
• Lymphocytic Hypophysitis: Autoimmune inflammation of the pituitary gland resulting in impaired hormone secretion under stress.
• Hypothalamic Dysfunction: Failure of the hypothalamus to secrete GHRH or CRH in response to hypoglycemia, resulting in a blunted pituitary response.
• Insulin Resistance: Detected when standard doses of insulin fail to lower the blood glucose level below 40 mg/dL, requiring a higher dose or rescheduling of the test.
• Normal Physiological Variation: Variations in peak response that help clinicians rule out organic disease in patients with constitutional delay of growth.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing highly accurate diagnostic reports with an efficient turnaround time. Because the Growth Hormone Stimulation Test by Insulin involves the analysis of multiple serial blood samples (typically 6 to 7 samples for both glucose and growth hormone), the laboratory utilizes advanced automated immunoassay platforms to ensure precision. The final consolidated report, which includes a detailed curve of glucose levels alongside corresponding growth hormone values, is typically available within 24 to 48 hours after the completion of the procedure.

Patients and their referring physicians can access reports easily through multiple digital channels. Chughtai Lab provides secure online report access via its official website and the Chughtai Lab Mobile App. Additionally, patients receive an automated SMS notification with a direct download link as soon as the clinical pathologist signs off on the results. Hard copies of the reports can also be collected from any of Chughtai Lab’s numerous collection centers located across Pakistan.

Growth Hormone Stimulation Test By Insulin Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Baseline Blood Glucose	70 – 100 mg/dL (Fasting)	>100 mg/dL (Impaired fasting glucose or Diabetes)
Nadir Blood Glucose (Hypoglycemia)	< 40 mg/dL (or >50% drop from baseline)	Failure to reach <40 mg/dL (Invalidates the test)
Peak Growth Hormone (Pediatric)	> 10.0 ng/mL (or >7.0 ng/mL depending on assay)	< 7.0 ng/mL (Indicates Growth Hormone Deficiency)
Peak Growth Hormone (Adult)	> 3.0 to 5.0 ng/mL	< 3.0 ng/mL (Severe Adult Growth Hormone Deficiency)
Peak Cortisol Level (HPA Axis)	> 18.0 mcg/dL (500 nmol/L)	< 18.0 mcg/dL (Indicates Secondary Adrenal Insufficiency)
Clinical Symptoms of Hypoglycemia	Mild sweating, warmth, palpitations, hunger	No symptoms (suggests failure to achieve target hypoglycemia) or severe neuroglycopenia (seizures, coma)
Somatotroph Secretory Capacity	Robust, prompt release of GH under stress	Blunted or flatline GH response (Pituitary hypoplasia, adenoma compression)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Growth Hormone Stimulation Test By Insulin?

• Experienced Healthcare Professionals: The test is conducted under the direct supervision of qualified medical doctors and trained nursing staff experienced in dynamic endocrine testing.
• Patient-Focused Care: Chughtai Lab prioritizes patient safety, ensuring continuous clinical monitoring and immediate availability of rescue protocols during hypoglycemia.
• Quality Diagnostic Services: Utilizing state-of-the-art automated immunoassay analyzers to deliver highly precise hormone measurements.
• Professional Reporting: Comprehensive reports featuring detailed serial curves of glucose and growth hormone levels, reviewed by expert clinical pathologists.
• Modern Diagnostic Approach: Adherence to international endocrine guidelines for the execution and interpretation of the Insulin Tolerance Test.
• Comfortable Environment: Dedicated testing areas designed to provide a calm and stress-free experience for both pediatric and adult patients.
• Convenient Location: An extensive network of diagnostic centers across Pakistan, making specialized testing accessible.
• Commitment to Accurate Diagnosis: Strict quality control measures and ISO-aligned laboratory standards to ensure the highest level of diagnostic reliability.